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Treatment of ex-breeder male NMRI mice with lipid mobilising factor isolated from the urine of cachectic cancer patients,
caused a signiﬁcant increase in glucose oxidation to CO2, compared with control mice receiving phosphate buffered saline.
Glucose utilisation by various tissues was determined by the 2-deoxyglucose tracer technique and shown to be elevated in
brain, heart, brown adipose tissue and gastrocnemius muscle. The tissue glucose metabolic rate was increased almost three-
fold in brain, accounting for the ability of lipid mobilising factor to decrease blood glucose levels. Lipid mobilising factor also
increased overall lipid oxidation, as determined by the production of
14CO2 from [
14C carboxy] triolein, being 67% greater
than phosphate buffered saline controls over a 24 h period. There was a signiﬁcant increase in [
14C] lipid accumulation in
plasma, liver and white and brown adipose tissue after administration of lipid mobilising factor. These results suggest that
changes in carbohydrate metabolism and loss of adipose tissue, together with an increased whole body fatty acid oxidation in
cachectic cancer patients, may arise from tumour production of lipid mobilising factor.
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Loss of whole body fat is a prominent feature of cancer cachexia,
with losses of up to 85% being reported (Fearon, 1992) in lung
cancer patients, who had lost 30% of their pre-illness stable weight.
Most studies suggest that loss of fat arises as a result of an
increased lipolysis, together with increased whole body fatty acid
oxidation. Thus increased plasma concentrations of glycerol, free
fatty acids (FFA) and triglycerides were observed in a heteroge-
neous group of cancer patients with an average loss of 13% of
their original body weight (Legaspi et al, 1987). Basal fatty acid
turnover was elevated by 25% above that for controls, and was
found to be similar to the rate observed for patients with severe
burns. Lipolysis was increased by 40% in patients in whom
complete triglyceride hydrolysis without re-esteriﬁcation was
observed, and there was a 20% increase in fatty acid oxidation.
Upregulation of catabolism, rather than defects in anabolism,
appear to be most important in the loss of lipid from human
adipose tissue in cancer cachexia. Thus Thompson et al (1993)
have shown a two-fold increase in the relative level of mRNA
for triglyceride lipase, while the relative levels of mRNA for lipo-
protein lipase (LPL) and fatty acid synthase were not signiﬁcantly
different between cancer patients and controls. This suggests that
cytokines such as tumour necrosis factor-a (TNF-a), interleukin-1
(IL-1), interleukin-6 (IL-6), interferon-g (IFN-g) and leukaemia-
inhibitory factor (LIF), which have been proposed to decrease
adipose tissue mass by decreasing synthesis of triglycerides
through inhibition of LPL (Berg et al, 1994) probably play a
minor role in the loss of lipid from human adipose tissue. It
therefore seems more likely that lipid mobilisation in cancer
cachexia can be attributed to tumour catabolic factors, such as
lipid mobilising factor (LMF), which acts directly on adipose
tissue with the release of FFA and glycerol in a manner similar
to that of lipolytic hormones (Beck and Tisdale, 1987). LMF
has been puriﬁed from the urine of patients with cancer cachexia
using a combination of ion exchange, exclusion and hydrophobic
interaction chromatographies (Todorov et al, 1998). Unlike poly-
peptide hormones stimulating lipolysis which are basic, LMF is
acidic and showed homology in amino acid sequence, electro-
phoretic mobility and immunoreactivity with the plasma protein
Zn-a2-glycoprotein (ZAG). Both LMF and ZAG stimulate adeny-
late cyclase in adipocyte plasma membranes in a GTP-dependent
process (Hirai et al, 1998). This suggests the two factors are simi-
lar, although they may differ in glycosylation. Administration of
LMF to obese mice produced a speciﬁc loss of carcass lipid, with-
out a change in body water or nonfat mass. Oxygen uptake by
interscapular brown adipose tissue (BAT) was increased three-
fold, providing evidence for increased lipid utilisation. Despite
fat mobilisation there was a decrease in blood glucose levels.
Hypoglycaemia occurs in mice bearing a cachexia-inducing
tumour (MAC16), although the mechanism by which this occurs
is not known (McDevitt and Tisdale, 1992).
The purpose of the present study was to investigate the effect of
LMF on glucose and lipid metabolism in vivo in order to quanti-
tate the effect on energy utilisation.
MATERIALS AND METHODS
Animals
Ex-breeder male NMRI mice (35–40 g) were obtained from our
own breeding colony and were fed a rat and mouse diet (Special
Diet Services, Witham, Essex, UK). All animal experiments
followed a strict protocol, agreed with the British Home Ofﬁce,
and the ethical guidelines that were followed meet the standards
required by the UKCCCR guidelines (Workman et al, 1998).
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D-[U-
14C]glucose (sp. act. 11.0 GBq mmol
71), 2-deoxy-D-
[2,6-
3H]glucose ([
3H]2DG; sp. act. 1.63 TBq mmol
71) and 2-
deoxy-D-[1-
14C]glucose ([
14C]2DG; sp. act. 2.072 MBq mmol
71),
were purchased from Amersham Lifesciences, (Bucks, UK).
[Carboxy
14C] Triolein (sp. act. 3.8 GBq mmol
71) was from
New England Nuclear (Southampton, UK).
Puriﬁcation of LMF
LMF was puriﬁed from the urine of weight losing patients with
pancreatic cancer using a combination of batch extraction on
DEAE cellulose and hydrophobic interaction chromatography as
previously described (Todorov et al, 1998). Urine was centrifuged
at 3000 g for 10 min to remove particulate material and diluted
with 4 vol 10 mM Tris. HCl, pH 8.0. DEAE cellulose (10 g l
71
of original urine) was then added and the mixture was stirred
for 2 h at 48C. The LMF–DEAE cellulose complex was isolated
by low speed centrifugation, and LMF eluted with 0.5 M NaCl in
10 mM Tris. HCl, pH 8.0. Bioactivity was monitored by the
release of glycerol from freshly isolated epididymal adipocytes
(Beck and Tisdale, 1987). The eluate was equilibrated against
PBS and concentrated to 1 ml before further puriﬁcation using
a Resource-Iso HPLC column (Pharmacia Biotech, St Albans,
Herts, UK) employing a decreasing (NH4)2SO4 concentration
from 1.5 M. Active fractions containing LMF eluted at 0.6 M
(NH4)2SO4 and were desalted before use by washing ﬁve times
against PBS using an Amicon ﬁltration cell. LMF eluted mainly
as a single protein band of Mr 43000, as determined by
Coomassie blue staining of a 12% SDS polyacrylamide gel
(Figure 1).
Treatment of animals
LMF (8 mg in 100 ml PBS) was administered b.d. by i.v. administa-
tion into the tail vein of ex-breeder male NMRI mice. This dose
was previously shown (Hirai et al, 1998) to be effective in lipid
depletion in vivo. Control animals received PBS alone. This was
repeated up to 48 h before the effect on glucose and lipid utilisa-
tion was measured.
Production of
14CO2 from D-[U-
14C] glucose
Animals were injected i.p. with 50 mCi kg
71 of D-[U-
14C] glucose
in 200 ml of 0.9% NaCl and placed in airtight metabolic cages into
which air was pumped through solid CaCO3 to absorb any CO2.
Metabolically produced
14CO2 was trapped in glass test tubes
containing 20 ml of a mixture of ethanolamine:ethoxyethanol
(1:4). At speciﬁc time intervals (0.5, 1, 2, 4 and 8 h) 0.5 ml
aliquots were taken and mixed with 10 ml Optiphase Hi-safe II
(Fisher Chemicals, Leics, UK), and the radioactivity was measured
in a Packard Tri-Carb 2000 CA scintillation analyser.
Glucose utilisation
Glucose utilisation by various tissues after LMF administration
was determined by the 2-deoxyglucose (2DG) tracer technique
(Mesazaros et al, 1987a,b), with starvation overnight and
throughout the experiment, but with ad libitum water. After
the overnight starvation mice were injected i.v. with 50 mCi kg
71
[
3H]2DG in 200 ml 0.9% NaCl and to determine the retention of
2-deoxyglucose-6-phosphate by the different tissues, a second i.v.
injection of 5 mCi kg
71 of [
14C]2DG was administered 35 min
after the unjection of the tritiated deoxyglucose. The accumula-
tion of phosphorylated metabolites of 2DG was measured in
selected tissues 60 min after the injection of [
3H]2DG. Mice were
killed by cervical dislocation and blood removed from the heart
for glucose measurement by the hexokinase-glucose 6-phosphate
dehydrogenase enzymatic assay (Sigma-Aldrich Co. Ltd., Dorset,
UK). The concentration of radioactivity in the blood was deter-
mined on deproteinised neutralised samples with a dual
3H/
14C
analyser. Tissues were homogenised in ice-cold 0.5 N perchloric
acid at the rate of 0.4 ml per 100 mg tissue wet weight using
a Camlab 563C homogeniser (speed 8) ﬁtted with a teﬂon pestle.
The homogenate was centrifuged for 15 min at 3000 r.p.m. and
the supernatant was neutralised to pH 7 with 10% w v
71 potas-
sium hydroxide, and the radioactivity was determined after the
removal of the insoluble potassium perchlorate. This gave the
total radioactivity of 2DG and its metabolites present in the
tissue. 2DGP was removed from the neutral extract by precipita-
tion with zinc sulphate/barium hydroxide and the difference
between the total radioactivity of the neutral extract and that
after removal of 2DGP represented the 2DGP content of the
tissue.
Glucose utilisation was calculated from the equation (Meszaros
et al, 1987a):
Rg 
Cm*T
LC T
o
 Cp*
Cp dt
where Rg is the tissue glucose metabolic rate (nmol min
71g
71),
Cm* (T) is the concentration of phosphorylated metabolites of
2DG in the tissue (d.p.m. g
71) at t=60 min, Cp is the blood
glucose (nmol ml
71), Cp* is the concentration of [
3H]2DG in
the blood (d.p.m. ml
71) and LC (lumped constant) is a dimen-
sionless correction factor for discrimination against 2DG in
glucose metabolic pathways. This was determined to be 0.46 in
NMRI mice (Mahony and Tisdale, 1990) using the method of Ferre
et al (1985).
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Figure 1 Electrophoretic separation of proteins on a 12% SDS polyacry-
lamide gel. Lane 1 molecular weight markers; Lane 2 LMF (5 mg protein)
eluted from Resource-Iso column at 0.6 M (NH4)2SO4.
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The absorption, accumulation and oxidation of an oral dose of
triolein was determined using the method of Oller do Nascimento
and Williamson (1986). [Carboxy
14C] triolein (0.33 mCi in 100 ml
normal saline) was administered by intragastric intubation to
NMRI mice previously administered either LMF or PBS. Immedi-
ately after administration animals were placed in airtight metabolic
cages and expired
14CO2 was collected over a 24 h period as
described above. At 5 and 24 h some of the animals were anaesthe-
tised and blood was collected by cardiac puncture. The complete
gastrointestinal tract was removed and homogenised in 5 ml of
3% perchloric acid. Lipids were extracted from organs and blood
by the method of Stansbie et al (1976). The extracted fatty acids
were dissolved in Optiphase Hi-safe II scintillation ﬂuid and the
radioactivity determined as above. Triolein absorption was calcu-
lated by subtracting the total gastrointestinal tract radioactivity
from that administered.
Statistical analysis
Results are expressed as mean+s.e.mean. Differences were deter-
mined by one-way Analysis of Variance (ANOVA) followed by
Tukey–Kramer multiple comparison test. P values less than 0.05
were considered statistically signiﬁcant.
RESULTS
The effect of LMF administration for 48 h on
14CO2 production
from D-[U-
14C] glucose is shown in Figure 2. This does not strictly
measure glucose oxidation, since recycling of label and transfer to
substrates such as lipids must also be considered, since they may
contribute to the
14CO2 produced. In both groups between 70
and 80% of the administered radiolabel was metabolised to
14CO2 during an 8 h period. However, there was an increase in
14CO2 production from mice administered LMF, which became
signiﬁcant after 2 h, and remained above that of mice administered
PBS alone over the 8 h experimental period.
In order to determine individual organ glucose utilisation after
LMF, the 2DG tracer method was used (Meszaros et al, 1987a,b).
The transport, cellular uptake and phosphorylation by hexokinase
of this analogue correlate with those of glucose, but because
2DGP cannot readily be metabolised further, it can be detected
in tissues containing little glucose-6-phosphatase, such as brain
and muscle (Lackner et al, 1984; Jenkins et al, 1986). The tissue
glucose metabolic rate (Rg) of LMF and PBS-treated mice is shown
in Figure 3. Treatment with LMF caused a signiﬁcant increase in
Rg in brain, heart, brown adipose tissue (BAT) and gastrocnemius
muscle, but a decrease in Rg in white adipose tissue (WAT) and
diaphragm. The decrease in Rg in WAT correlates with an
increased lipid utilisation (Figure 4), although the reason for the
difference between the two muscle types is not known. Since the
brain is the main utilizer of glucose, the almost three-fold increase
in Rg value observed in the presence of LMF (Figure 3) would
account for the previously reported (Hirai et al, 1998) ability of
LMF to decrease blood glucose levels.
The primary effect of LMF is on lipid mobilisation and utili-
sation through an increased rate of lipolysis (Hirai et al, 1998),
and through stimulation of increased expression of mRNA for
uncoupling protein 1 (UCP1) in BAT and uncoupling protein
2 (UCP2) in BAT, skeletal muscle and liver (Bing et al, 2002).
The effect of LMF on the ability of mice to deal with adminis-
tered lipid was investigated by intragastric intubation with [
14C
carboxy] triolein 48 h after treatment with either LMF or PBS
and the absorption into various organs was monitored over a
6 h period (Figure 4). There was a signiﬁcant increase in [
14C]
lipid accumulation in plasma, liver, WAT and BAT of LMF-trea-
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Figure 2 Production of
14CO2 from D-[U-
14C] glucose by NMRI mice
administered either LMF for 48 h or PBS as described in Materials and
Methods. There were 12 mice in each group. Differences from control
are indicated as either
bP50.01 or
dP50.001.
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Figure 3 Tissue glucose metabolic rate (Rg) in mice administered either
PBS (closed box) or LMF (open box) as described in Materials and Meth-
ods. There were 12 mice in each group. Differences from control are indi-
cated as either
aP50.05 or
dP50.001.
3
2.5
2
1.5
1
0.5
0
P
e
r
c
e
n
t
a
g
e
 
a
c
c
u
m
u
l
a
t
i
o
n
 
o
f
 
T
r
i
o
l
e
i
n
 
(
p
e
r
 
g
 
t
i
s
s
u
e
)
Plasma
Liver
White adipose
Brown adipose
Gastrocnemius
Brain
Kidney
Heart
d
b
a
b
Figure 4 Tissue [
14C] lipid accumulation (percentage absorbed dose per
g tissue over a 6 h period) from [
14C-carboxy] triolein administered enter-
ally by gastric intubation as described in Materials and Methods after admin-
istration of either PBS (closed box) or LMF (open box). There were 12
mice in each group. Differences from control are indicated as either
aP50.05,
bP50.01 or
dP50.001.
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gastrocnemius muscle, brain, kidney or heart. This distribution
correlates with what would be expected from a decrease in lipid
in plasma and WAT, and an increase in lipid in liver (Bing et al,
2002).
The rate of oxidation of [
14C carboxy] triolein to
14CO2 for
LMF and PBS-treated mice is shown in Figure 5. Lipid oxidation
increased exponentially during the ﬁrst 5 h after administration
of triolein in both groups and then levelled off up to 24 h. Animals
administered LMF showed an increased rate of oxidation of [
14C
carboxy] triolein during the initial phase and overall lipid oxida-
tion was 67% greater during the 24 h period. This result
conﬁrms the ability of LMF to increase lipid utilization in vivo.
DISCUSSION
Loss of fat occurs when the metabolic demands on an organism are
high, since fat constitutes 90% of the adult fuel reserves. Mobilisa-
tion of fat in cancer cachexia provides a fuel source for the host
when the metabolic demand is high. Increased glucose utilisation
by the tumour (Mulligan and Tisdale, 1991) results in an increased
lactate production, resulting in an increased operation of the Cori
cycle (Holroyde et al, 1975), which consumes 6 moles of ATP per
mole of glucose formed. Thus cancer patients have been reported
to have an increased oxidation of fat (Hyltander et al, 1991) and
an increased rate of removal of infused lipids from the blood
(Waterhouse and Nye, 1961). Increased utilisation of fatty acids
as the preferred energy source has been observed even in the
presence of high glucose concentrations (Waterhouse and Kemper-
man, 1971). This suggests that in the presence of certain tumours
host tissues may increase their utilisation of fatty acids as an energy
source. A number of studies have shown that such tumours elabo-
rate lipid mobilising factors, which increase lipolysis in adipose
tissue through the normal cyclic AMP-mediated pathway.
LMF has been extracted from the urine of patients with carcino-
ma of the stomach, rectum, pancreas, ovary and liver, where weight
loss was established, but was absent from the urine of patients
without weight loss, or from normal subjects (Todorov et al,
1998). This suggests that LMF may be involved in lipid depletion
in cancer cachexia, although no measurements have been made
on circulating levels of LMF. LMF of similar molecular weight
and electrophoretic mobility was also isolated from the cachexia-
inducing MAC16 murine tumour and is most likely involved in
lipid depletion in this model (Beck and Tisdale, 1987), since there
is no evidence for cytokine involvement (Mulligan et al, 1992a).
The concentration of LMF which we have employed in the present
study (8 mg per injection) was chosen based on the content of LMF
in the MAC16 tumour (Todorov et al, 1998) and this concentra-
tion was previously found to be effective in depletion of adipose
tissue in normal mice (Hirai et al, 1998). Maximum lipolytic activ-
ity was observed in mice bearing the MAC16 tumour when they
had lost 15% of their body weight (Groundwater et al, 1990). At
this point the animals had lost 40% of their body fat (Smith and
Tisdale, 1993), which is close to the value (42%) obtained by the
injection of normal NMRI mice with 8 mg LMF bi-daily (Hirai et
al, 1998). Many of the effects of LMF in mice are similar to those
produced by the MAC16 tumour. Thus both produce hypoglycae-
mia (McDevitt and Tisdale, 1992), lipid depletion (Beck and
Tisdale, 1987) and an increased
14CO2 production from [
14C] trio-
lein (Mulligan et al, 1992b) indicative of an increase in lipid
utilisation. Hypoglycaemia induced by LMF arises from an
increased glucose consumption by the brain, heart, BAT and
gastrocnemius muscle. The mechanism for the increased glucose
consumption is not known, but appears to occur in a non-insu-
lin-dependent manner (Islam-Ali and Tisdale, 2001a) and
probably arises from an increased glucose transport and phosphor-
ylation due to an increase in GLUT1 or GLUT3. LMF increases
metabolic substrate utilisation in vivo. Thus overall glucose oxida-
tion was increased by LMF, as measured by the formation of
14CO2
from D-[U-
14C] glucose. LMF also produced an increase in oxida-
tion of lipid, and the increased lipid accumulation by BAT and
WAT after LMF administration may be due to rapid lipid turnover
in these tissues. LMF has been shown not only to initiate lipolysis,
but also to prime adipose tissue towards lipolytic stimuli by
increasing Gas expression with a reciprocal decrease in Gai
(Islam-Ali et al, 2001b). This together with the increase in UCP1
mRNA in BAT (Bing et al, 2002) after LMF suggests a role also
in the disposal of excess lipid. Large amounts of micro-droplets
of lipid have been shown to be deposited in hepatocytes after
LMF administration (Bing et al, 2002), suggesting that lipid is
mobilised at a faster rate than it can be metabolised in BAT, and
that excess lipid is stored in the liver.
The results of this study conﬁrm that LMF stimulates oxidative
metabolism in whole animals, thus accounting for the lipid deple-
tion (Hirai et al, 1998). The similarity between the effects of LMF
on fuel disposal and that seen in cancer cachexia suggests that it
may be responsible for the progressive lipid depletion.
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